Overview

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This ia a multicenter, Single-Arm, Open-Label Phase I Clinical Study Evaluating the Safety and Tolerability of Pelareorep Combined with Paclitaxel Injection and the Intracorporal Process of Pelareorep in Chinese Patients with Advanced or Metastatic Breast Cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Adlai Nortye Biopharma Co., Ltd.
Treatments:
Paclitaxel